Azithromycin Can Prolong QT Interval and Suppress Ventricular Contraction, but Will Not Induce Torsade de Pointes

Cardiovascular Toxicology

Volumn 15, Issue 3, 2015, Pages 232-240

  Ohara, Hiroshi ^a   Nakamura, Yuji ^a   Watanabe, Yudai ^a   Cao, Xin ^a   Yamazaki, Yukiko ^a   Izumi Nakaseko, Hiroko ^a   Ando, Kentaro ^a   Yamazaki, Hiroshi ^b   Yamazaki, Junichi ^a   Ikeda, Takanori ^a   Sugiyama, Atsushi ^a  

^a TOHO UNIVERSITY   (Japan)

^b SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Atrioventricular block; Azithromycin; IKr; QT prolongation; Torsade de pointes; Ventricular contraction

Indexed keywords

AZITHROMYCIN; CALCIUM CHANNEL; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEAGLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; ELECTROCARDIOGRAM; ELECTROPHYSIOLOGY; FEMALE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE REFRACTORY PERIOD; HEART OUTPUT; HEART RATE; HEART REPOLARIZATION; HEART VENTRICLE CONTRACTION; INOTROPISM; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PHARMACOLOGY; POTASSIUM CURRENT; PR INTERVAL; PRIORITY JOURNAL; QRS INTERVAL; QT INTERVAL; QT PROLONGATION; QTC INTERVAL; TORSADE DES POINTES; VASCULAR RESISTANCE; ANIMAL; CHEMICALLY INDUCED; DOG; DRUG EFFECTS; HEART CONTRACTION; HEART VENTRICLE; LONG QT SYNDROME; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME FACTOR;

CANIS FAMILIARIS;

ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; DOGS; FEMALE; HEART VENTRICLES; LONG QT SYNDROME; MALE; MYOCARDIAL CONTRACTION; TIME FACTORS; TORSADES DE POINTES;

EID: 84930415949     PISSN: 15307905     EISSN: 15590259     Source Type: Journal    
DOI: 10.1007/s12012-014-9289-4     Document Type: Article

References (28)

1. Parnham, M. J., Haber, V. E., Giamarellos-Bourboulis, E. J., Perletti, G., Verleden, G. M., & Vos, R. (2014). Azithromycin: Mechanisms of action and their relevance for clinical applications. Pharmacology & Therapeutics,143, 225–245.
2. Ray, W. A., Murray, K. T., Hall, K., Arbogast, P. G., & Stein, C. M. (2012). Azithromycin and the risk of cardiovascular death. New England Journal of Medicine,366, 1881–1890.
3. Thomsen, M. B., Beekman, J. D., Attevelt, N. J., Takahara, A., Sugiyama, A., Chiba, K., et al. (2006). No proarrhythmic properties of the antibiotics moxifloxacin or azithromycin in anaesthetized dogs with chronic-AV block. British Journal of Pharmacology,149, 1039–1048.
4. Santos, N., Oliveira, M., Galrinho, A., Oliveira, J. A., Ferreira, L., & Ferreira, R. (2010). QT interval prolongation and extreme bradycardia after a single dose of azithromycin. Revista Portuguesa de Cardiologia,29, 139–142.
5. Huang, B. H., Wu, C. H., Hsia, C. P., & Yin Chen, C. (2007). Azithromycin-induced torsade de pointes. Pacing and Clinical Electrophysiology,30, 1579–1582.
6. Kezerashvili, A., Khattak, H., Barsky, A., Nazari, R., & Fisher, J. D. (2007). Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors. Journal of Interventional Cardiac Electrophysiology,18, 243–246.
7. Tilelli, J. A., Smith, K. M., & Pettignano, R. (2006). Life-threatening bradyarrhythmia after massive azithromycin overdose. Pharmacotherapy,26, 147–150.
8. Kim, M. H., Berkowitz, C., & Trohman, R. G. (2005). Polymorphic ventricular tachycardia with a normal QT interval following azithromycin. Pacing and Clinical Electrophysiology,28, 1221–1222.
9. Samarendra, P., Kumari, S., Evans, S. J., Sacchi, T. J., & Navarro, V. (2001). QT prolongation associated with azithromycin/amiodarone combination. Pacing and Clinical Electrophysiology,24, 1572–1574.
10. Svanstrom, H., Pasternak, B., & Hviid, A. (2013). Use of azithromycin and death from cardiovascular causes. New England Journal of Medicine,368, 1704–1712.
11. Sugiyama, A. (2008). Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts. British Journal of Pharmacology,154, 1528–1537.
12. Ishizaka, T., Takahara, A., Iwasaki, H., Mitsumori, Y., Kise, H., Nakamura, Y., et al. (2008). Comparison of electropharmacological effects of bepridil and sotalol in halothane-anesthetized dogs. Circulation Journal,72, 1003–1011.
13. Yoshida, H., Sugiyama, A., Satoh, Y., Ishida, Y., Kugiyama, K., & Hashimoto, K. (2002). Effects of disopyramide and mexiletine on the terminal repolarization process of the in situ heart assessed using the halothane-anesthetized in vivo canine model. Circulation Journal,66, 857–862.
14. Kise, H., Nakamura, Y., Hoshiai, M., Sugiyama, H., Sugita, K., & Sugiyama, A. (2010). Cardiac and haemodynamic effects of tacrolimus in the halothane-anaesthetized dog. Basic & Clinical Pharmacology & Toxicology,106, 288–295.
15. Chiba, K., Sugiyama, A., Hagiwara, T., Takahashi, S., Takasuna, K., & Hashimoto, K. (2004). In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome. European Journal of Pharmacology,486, 189–200.
16. 1 blocker terfenadine-induced torsades de pointes arrhythmias. British Journal of Pharmacology,147, 634–641.
17. Sugiyama, A., Ishida, Y., Satoh, Y., Aoki, S., Hori, M., Akie, Y., et al. (2002). Electrophysiological, anatomical and histological remodeling of the heart to AV block enhances susceptibility to arrhythmogenic effects of QT-prolonging drugs. Japanese Journal of Pharmacology,88, 341–350.
18. Thomsen, M. B., Verduyn, S. C., Stengl, M., Beekman, J. D., de Pater, G., van Opstal, J., et al. (2004). Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation,110, 2453–2459.
19. Thomsen, M. B., Volders, P. G., Beekman, J. D., Matz, J., & Vos, M. A. (2006). Beat-to-beat variability of repolarization determines proarrhythmic outcome in dogs susceptible to drug-induced torsades de pointes. Journal of the American College of Cardiology,48, 1268–1276.
20. Milberg, P., Eckardt, L., Bruns, H. J., Biertz, J., Ramtin, S., Reinsch, N., et al. (2002). Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: Fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. Journal of Pharmacology and Experimental Therapeutics,303, 218–225.
21. Van de Water, A., Verheyen, J., Xhonneux, R., & Reneman, R. S. (1989). An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. Journal of Pharmacological Methods,22, 207–217.
22. Kr channel blocker sematilide on the relationship between ventricular repolarization, refractoriness and onset of torsades de pointes. Japanese Journal of Pharmacology,88, 414–421.
23. Sharma, K., & Mullangi, R. (2013). A concise review of HPLC, LC-MS and LC-MS/MS methods for determination of azithromycin in various biological matrices. Biomedical Chromatography,27, 1243–1258.
24. Fridericia, L. S. (2003). The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. 1920. Annals of Noninvasive Electrocardiology,8, 343–351.
25. Satoh, T., & Zipes, D. P. (1996). Rapid rates during bradycardia prolong ventricular refractoriness and facilitate ventricular tachycardia induction with cesium in dogs. Circulation,94, 217–227.
26. Brennan, M., Palaniswami, M., & Kamen, P. (2001). Do existing measures of Poincare plot geometry reflect nonlinear features of heart rate variability? IEEE Transactions on Biomedical Engineering,48, 1342–1347.
27. Tamargo, J., De Miguel, B., & Tejerina, M. T. (1982). A comparison of josamycin with macrolides and related antibiotics on isolated rat atria. European Journal of Pharmacology,80, 285–293.
28. Shiina, H., Sugiyama, A., Takahara, A., Satoh, Y., & Hashimoto, K. (2000). Comparison of the electropharmacological effects of verapamil and propranolol in the halothane-anesthetized in vivo canine model under monophasic action potential monitoring. Japanese Circulation Journal,64, 777–782.